EP1786408A4 - Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency - Google Patents

Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Info

Publication number
EP1786408A4
EP1786408A4 EP05771627A EP05771627A EP1786408A4 EP 1786408 A4 EP1786408 A4 EP 1786408A4 EP 05771627 A EP05771627 A EP 05771627A EP 05771627 A EP05771627 A EP 05771627A EP 1786408 A4 EP1786408 A4 EP 1786408A4
Authority
EP
European Patent Office
Prior art keywords
prevention
manufacture
treatment
pharmaceutical preparation
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05771627A
Other languages
German (de)
French (fr)
Other versions
EP1786408A1 (en
Inventor
Taru Blom
Janne Komi
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Medical Ltd
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/en
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of EP1786408A1 publication Critical patent/EP1786408A1/en
Publication of EP1786408A4 publication Critical patent/EP1786408A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05771627A 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency Withdrawn EP1786408A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (en) 2004-09-21 2004-09-21 A method of treating or preventing an androgen deficiency
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (2)

Publication Number Publication Date
EP1786408A1 EP1786408A1 (en) 2007-05-23
EP1786408A4 true EP1786408A4 (en) 2010-07-28

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05771627A Withdrawn EP1786408A4 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Country Status (10)

Country Link
EP (1) EP1786408A4 (en)
JP (1) JP2008511615A (en)
KR (1) KR20070059110A (en)
AU (1) AU2005279178A1 (en)
BR (1) BRPI0514701A (en)
CA (1) CA2578852A1 (en)
MX (1) MX2007002606A (en)
NO (1) NO20071160L (en)
RU (1) RU2007112114A (en)
WO (1) WO2006024689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363344B2 (en) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド Process for the preparation of triphenylbutene derivatives useful for therapy
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9975832B2 (en) 2014-12-29 2018-05-22 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (en) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
JP2003534375A (en) * 2000-05-26 2003-11-18 フィッチ，ハリー Treatment of androgen deficiency in men with selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ES2319785T3 (en) * 2001-11-29 2009-05-12 Gtx, Inc. PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY ANDROGEN PRIVACY.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUSCHEK ERIK J J ET AL: "Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 539 - 546, XP002586475, ISSN: 0804-4643 *
See also references of WO2006024689A1 *
STEINER MITCHELL S ET AL: "Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.", CLINICAL PROSTATE CANCER JUN 2003 LNKD- PUBMED:15046680, vol. 2, no. 1, June 2003 (2003-06-01), pages 24 - 31, XP009134590, ISSN: 1540-0352 *

Also Published As

Publication number Publication date
MX2007002606A (en) 2007-05-15
AU2005279178A1 (en) 2006-03-09
EP1786408A1 (en) 2007-05-23
NO20071160L (en) 2007-05-25
JP2008511615A (en) 2008-04-17
BRPI0514701A (en) 2008-06-24
CA2578852A1 (en) 2006-03-09
WO2006024689A1 (en) 2006-03-09
KR20070059110A (en) 2007-06-11
RU2007112114A (en) 2008-10-10

Similar Documents

Publication Publication Date Title
EP1781183A4 (en) Devices and methods for pyloric anchoring
EP1962722A4 (en) Methods and systems for aneurysm treatment using filling structures
EP1733310A4 (en) System and method for creating orthotics
IL181043A0 (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ZA200701156B (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
GB0420016D0 (en) Controlled release oral delivery system
HK1130234A1 (en) Closure device providing visual confirmation of occlusion
EP1972251A4 (en) Capsule container and administration method using the same
IL209402A (en) Process for the preparation of opioid receptor modulators and opioid receptor modulators prepared thereby
EP1786408A4 (en) Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
IL185003A0 (en) Androgen receptor modulator compounds and methods
PL1786744T3 (en) Method for retarding plaster setting and plaster preparation
ZA200700483B (en) Process for the preparation 2-substituted-derivatives of estrone and estradiol
PT2063881T (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
ZA200705086B (en) Catalytic materials and method for the preparation thereof
EP1809266A4 (en) Anticancer compounds and methods
ZA200702038B (en) Pharmaceutical composition drospirenone and ethynyle-stradiol
EP1765373A4 (en) Ozonidzed pharmaceutical composition and method
HK1102395A1 (en) Indene derivatives and process for the preparation thereof
IL181819A (en) Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds
EP1726313A4 (en) Drug for preventing and treating arteriosclerosis
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
EP1756036A4 (en) Indene derivatives and process for the preparation thereof
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
HUP0401170A2 (en) Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOMI, JANNE

Inventor name: BLOM, TARU

Inventor name: LAMMINTAUSTA, RISTO

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/085 20060101AFI20100615BHEP

Ipc: A61K 31/10 20060101ALI20100615BHEP

Ipc: A61P 5/32 20060101ALI20100615BHEP

Ipc: A61K 31/135 20060101ALI20100615BHEP

Ipc: A61K 31/395 20060101ALI20100615BHEP

Ipc: A61K 31/4164 20060101ALI20100615BHEP

Ipc: A61P 5/26 20060101ALI20100615BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100628

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110126